secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2021-10-18T23:59:59+00:00
Accession:  0001628280-21-020176
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics appoints Keith Maher, MD to Board under Armistice Capital right
--------------------------------------------------------------------------------

- Keith Maher, MD appointed to board effective Oct 15, 2021; term until 2022 annual meeting.
- Maher is employed by Armistice Capital Master Fund, a significant stockholder; CIO Steven J. Boyd already on board.
- Armistice participated in five offerings since Feb 2020, including 5.45M shares in Sept 2021 offering raising $29.3M net.
- Armistice purchased shares in each offering on same terms as other investors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828021020176/0001628280-21-020176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828021020176/avtx-20211015.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-020176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer